RxDoctor Payments Data

Andrew Benn, MD

Interventional Cardiology · Walnut Creek, CANPI 1851329270

Payments from drug & device makers

$121,838in general payments, 2019–2025

Across 439 payments — averaging $277.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$98K
  • E.r. Squibb & Sons, L.L.C.$12K
  • Boston Scientific$6K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$581
  • Novartis$477
  • AstraZeneca$452
  • plus $4K from 30 others

What the payments were for

  • Consulting fees$5000%
  • Speaking & faculty fees$104,88586%
  • Travel & lodging$7,4246%
  • Food & beverage$8,8617%
  • Education$1680%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$121,838 in reported general payments places this provider in the 80th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$1,050,820
Medicare patients
2,350
Services billed
39,328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis44$1,079,110
EliquisApixaban714$982,022
XareltoRivaroxaban136$172,582
Repatha SureclickEvolocumab129$157,581
FarxigaDapagliflozin Propanediol72$79,664
JardianceEmpagliflozin80$76,217
EntrestoSacubitril/Valsartan42$58,670
MultaqDronedarone Hcl36$53,156
Praluent PenAlirocumab71$49,625
Rosuvastatin Calcium742$15,970
NexletolBempedoic Acid18$14,113
Ezetimibe433$13,280
VascepaIcosapent Ethyl14$10,542
Atorvastatin Calcium775$9,309
NexlizetBempedoic Acid/Ezetimibe16$9,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$98,411$2,061,131758 claims
Johnson & JohnsonXarelto$140$172,582136 claims
AstraZenecaFarxiga$452$79,66472 claims
Boehringer IngelheimJardiance$226$76,21780 claims
NovartisEntresto$477$58,67042 claims
Sanofi-aventis U.S. LLCMultaq$30$53,15636 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$229$23,13834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →